Abbott (ABT) Stock Rated Buy on Strong Diabetes Trial Results [Yahoo! Finance]
Abbott Laboratories (ABT)
Last abbott laboratories earnings: 4/16 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
abbott.com/investors.html
Company Research
Source: Yahoo! Finance
encouraging results from Abbott Laboratories (NYSE:ABT)'s FreeDM trial, Benchmark reiterated a Buy rating and $145 price target for the company's shares on March 13. In comparison to individuals using whole blood glucose meters with fingerstick blood samples, the trial demonstrated that patients with Type 2 diabetes on basal insulin therapy who employed FreeStyle Libre continuous glucose monitoring technology achieved better glucose results. The findings from the UK trial were supported by a second interventional trial from Italy delivered at the same conference. Both results emphasize the need for expanded insurance coverage of continuous glucose monitoring in European nations where Libre has not been officially covered. Although no decision is expected very soon, the CMS is thinking about expanding compensation in the US. According to Benchmark, as one of the top providers of continuous glucose monitoring, Abbott Laboratories (NYSE:ABT) is well-positioned to profit from this dev
Show less
Read more
Impact Snapshot
Event Time:
ABT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABT alerts
High impacting Abbott Laboratories news events
Weekly update
A roundup of the hottest topics
ABT
News
- Abbott hosts conference call for first-quarter earningsPR Newswire
- Is It Time To Reconsider Abbott Laboratories (ABT) After Recent Share Price Weakness? [Yahoo! Finance]Yahoo! Finance
- John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screeningPR Newswire
- Medtronic's OmniaSecure defib lead nets another FDA approval [Yahoo! Finance]Yahoo! Finance
- Abbott completes acquisition of Exact SciencesPR Newswire
ABT
Earnings
- 1/22/26 - In-Line
ABT
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/25/26 - Form 4
- 3/25/26 - Form 3
- ABT's page on the SEC website